Apogee Therapeutics (APGE) to Release Earnings on Tuesday

Apogee Therapeutics (NASDAQ:APGE) is expected to be announcing its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect the company to announce earnings of ($1.14) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Wednesday, November 12, 2025 at 12:30 PM ET.

Apogee Therapeutics (NASDAQ:APGE) last released its earnings results on Monday, August 11th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.03) by ($0.10). On average, analysts expect Apogee Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Apogee Therapeutics Stock Performance

APGE traded down $0.67 on Tuesday, hitting $53.68. 79,111 shares of the company were exchanged, compared to its average volume of 727,127. Apogee Therapeutics has a 12 month low of $26.20 and a 12 month high of $63.50. The company has a market cap of $2.48 billion, a PE ratio of -13.15 and a beta of 1.50. The stock’s fifty day moving average is $44.23 and its 200-day moving average is $40.88.

Insiders Place Their Bets

In other Apogee Therapeutics news, insider Carl Dambkowski sold 5,110 shares of Apogee Therapeutics stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $39.80, for a total value of $203,378.00. Following the completion of the transaction, the insider directly owned 284,733 shares of the company’s stock, valued at $11,332,373.40. The trade was a 1.76% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last ninety days, insiders sold 10,560 shares of company stock valued at $409,524. 42.77% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of APGE. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Apogee Therapeutics by 2.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,529 shares of the company’s stock worth $921,000 after purchasing an additional 694 shares during the last quarter. Millennium Management LLC raised its position in Apogee Therapeutics by 100.0% during the 1st quarter. Millennium Management LLC now owns 260,335 shares of the company’s stock worth $9,726,000 after purchasing an additional 130,164 shares during the last quarter. Creative Planning bought a new position in Apogee Therapeutics during the 2nd quarter worth $392,000. Legal & General Group Plc grew its holdings in Apogee Therapeutics by 7.4% during the 2nd quarter. Legal & General Group Plc now owns 27,689 shares of the company’s stock worth $1,203,000 after acquiring an additional 1,907 shares during the period. Finally, Russell Investments Group Ltd. grew its holdings in Apogee Therapeutics by 10,570.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 21,768 shares of the company’s stock worth $945,000 after acquiring an additional 21,564 shares during the period. 79.04% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have weighed in on APGE. Wedbush reissued an “outperform” rating and set a $90.00 price target on shares of Apogee Therapeutics in a research report on Monday, August 11th. Craig Hallum began coverage on Apogee Therapeutics in a research report on Monday. They set a “buy” rating and a $109.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Apogee Therapeutics in a research report on Wednesday, October 8th. Royal Bank Of Canada upped their target price on Apogee Therapeutics from $60.00 to $70.00 and gave the company an “outperform” rating in a research report on Monday. Finally, Mizuho initiated coverage on Apogee Therapeutics in a research report on Tuesday, October 21st. They issued an “outperform” rating and a $105.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $96.50.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.